Huayu Pharmaceutical won in the first half of the year and last year
Huayu Pharmaceutical Profile
Huayu Pharmaceutical (6621), which was reinvested by Jianya (4130), was listed on the Xing Cabinet yesterday (18). The company benefited from the sales growth of anti-sticking solutions, tumor monitoring systems and other products, and EPS reached 0.4 yuan in the first half of this year, which has earned the whole of last year. Chen Zheng, chairman of Huayu Pharmaceutical, said that in addition to promoting its medical service projects to the international market, it is also actively developing new liver-protecting drugs.
Huayu Pharmaceutical has a share capital of 268 million yuan, and Jianya is the largest corporate shareholder. Huayu Pharmaceutical’s revenue last year was 154 million yuan, with a pre-tax net profit of 5.88 million yuan and an after-tax net profit of 0.24 yuan per share, and in the first half of this year, the revenue was 84.81 million yuan, the pre-tax net profit was 10.55 million yuan, and the EPS reached 0.4 yuan.
Chen Zheng said that Huayu Pharmaceutical is a boutique company, focusing on the development of new liver-protecting drugs, and at the same time developing tumor detection, tumor ablation, and providing personalized medical services such as a new generation of neuromedical biomarkers and anti-cancer drug blood concentration monitoring.
Huayu’s main products are anti-sticking solution ADEPT, tumor monitoring system (DR-70 and EZ Detect), RFA tumor ablation system and anti-cancer drug Killic blood concentration monitoring system. ADEPT can be used in abdominal and pelvic surgery to prevent sticking in all directions.
DR-70 is a new generation of colorectal cancer recurrence tracking detection reagent, the sensitivity and specificity are better than the existing products, the product will actively expand the market, Turkey, Southeast Asia and other markets, Chinese mainland combined with the Shiji China sales team, to seize China’s new colorectal cancer market of more than 500,000 per year.
In addition, the RFA tumor ablation system is a safe, minimally invasive, effective and low-pain tumor treatment option for tumors in the liver, thyroid nodules, kidneys, lungs or other organs in the abdominal cavity.
In terms of blood concentration monitoring system for anti-cancer drugs, the first blood concentration monitoring anti-cancer drug authorized by the introduction of partner Saladax Technology has completed all certification work and will be officially launched in the fourth quarter of this year.
As for the new drug part, Huayu Pharmaceutical’s first new ingredient and new drug, K-Li, is an antidote to methanol or ethylene glycol poisoning; The pharmacological mechanism of Kangli-Hydroxate ethanol dehydrogenase inhibitor can be developed into a new drug for liver protection. The new oral drug UPN161, which has been developed by Kang Lix, can reduce the esophageal cancer and liver cancer caused by alcohol consumption. It is expected that in 2018, the new oral dosage form will apply for IND from the Ministry of Health and Welfare and enter the human clinical trial stage.
(Business Times)
